Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Abiomed, Inc. (ABMD)

NEW YORK, Aug. 6, 2019

The investigation concerns whether Abiomed and certain of its officers and/or directors have violated federal securities laws.

On August 1, 2019, Abiomed announced its financial results for the first quarter of 2019.  Among other results, Abiomed announced its third consecutive quarter of slowing revenue growth, and the Company's full-year guidance expectations fell roughly $22 million short of market expectations.  On this news, Abiomed's stock price fell sharply on August 1, 2019.

If you are aware of any facts relating to this investigation, or purchased Abiomed shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/abmd.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com